Now showing items 1384-1403 of 3194

    • IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance. 

      Selfe, J; Goddard, NC; McIntyre, A; Taylor, KR; Renshaw, J; Popov, SD; Thway, K; Summersgill, B; Huddart, RA; Gilbert, DC; Shipley, JM (2018-02)
      Testicular germ cell tumours (TGCTs) are the most frequent malignancy and cause of death from solid tumours in the 20- to 40-year age group. Although most cases show sensitivity to cis-platinum-based chemotherapy, this is ...
    • IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL) 

      Del Giudice, I; Davis, Z; Matutes, E; Osuji, N; Parry-Jones, N; Morilla, A; Brito-Babapulle, V; Oscier, D; Catovsky, D (2006-07)
      B-prolymphocytic leukemia (B-PLL) is a rare disease with poor prognosis. To further characterize the biological features of this disease, we analyzed immunoglobulin heavy chain (IgVH) mutations, ZAP-70 and CD38 in 19 cases ...
    • IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. 

      Calcinotto, A; Spataro, C; Zagato, E; Di Mitri, D; Gil, V; Crespo, M; De Bernardis, G; Losa, M; Mirenda, M; Pasquini, E; Rinaldi, A; Sumanasuriya, S; Lambros, MB; Neeb, A; Lucianò, R; Bravi, CA; Nava-Rodrigues, D; Dolling, D; Prayer-Galetti, T; Ferreira, A; Briganti, A; Esposito, A; Barry, S; Yuan, W; Sharp, A; de Bono, J; Alimonti, A (2018-07)
      Patients with prostate cancer frequently show resistance to androgen-deprivation therapy, a condition known as castration-resistant prostate cancer (CRPC). Acquiring a better understanding of the mechanisms that control ...
    • Image intensity normalisation by maximising the Siddon line integral in the joint intensity distribution space 

      Kalemis, A; Binnie, DM; Flower, MA; Ott, RJ (ELSEVIER SCIENCE BV, 2009-12)
      This paper presents a novel data-driven method for image intensity normalisation, which is a prerequisite step for any kind of image comparison. The method involves a novel application of the Siddon algorithm that was ...
    • Imagery rescripting for psychological disorder following cancer: A case study 

      Whitaker, KL; Brewin, CR; Watson, M (BRITISH PSYCHOLOGICAL SOC, 2010-02)
      Objectives. Intrusive memories have been identified in cancer patients and associated with psychological distress and maladaptive adjustment. Imagery rescripting is a psychological therapy that has proved successful for ...
    • Imaging and dosimetry for radium-223: the potential for personalized treatment. 

      Flux, GD (2017-08)
      Radium-223 (223Ra) offers a new option for the treatment of bone metastases from prostate cancer. As cancer treatment progresses towards personalization, the potential for an individualized approach is exemplified in ...
    • Imaging biomarker roadmap for cancer studies. 

      O'Connor, JPB; Aboagye, EO; Adams, JE; Aerts, HJWL; Barrington, SF; Beer, AJ; Boellaard, R; Bohndiek, SE; Brady, M; Brown, G; Buckley, DL; Chenevert, TL; Clarke, LP; Collette, S; Cook, GJ; deSouza, NM; Dickson, JC; Dive, C; Evelhoch, JL; Faivre-Finn, C; Gallagher, FA; Gilbert, FJ; Gillies, RJ; Goh, V; Griffiths, JR; Groves, AM; Halligan, S; Harris, AL; Hawkes, DJ; Hoekstra, OS; Huang, EP; Hutton, BF; Jackson, EF; Jayson, GC; Jones, A; Koh, D-M; Lacombe, D; Lambin, P; Lassau, N; Leach, MO; Lee, T-Y; Leen, EL; Lewis, JS; Liu, Y; Lythgoe, MF; Manoharan, P; Maxwell, RJ; Miles, KA; Morgan, B; Morris, S; Ng, T; Padhani, AR; Parker, GJM; Partridge, M; Pathak, AP; Peet, AC; Punwani, S; Reynolds, AR; Robinson, SP; Shankar, LK; Sharma, RA; Soloviev, D; Stroobants, S; Sullivan, DC; Taylor, SA; Tofts, PS; Tozer, GM; van Herk, M; Walker-Samuel, S; Wason, J; Williams, KJ; Workman, P; Yankeelov, TE; Brindle, KM; McShane, LM; Jackson, A; Waterton, JC (2017-03)
      Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs used daily in oncology include clinical TNM stage, objective response and left ventricular ejection fraction. Other CT, MRI, PET ...
    • Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. 

      Perez-Lopez, R; Tunariu, N; Padhani, AR; Oyen, WJG; Fanti, S; Vargas, HA; Omlin, A; Morris, MJ; de Bono, J; Koh, D-M (2019-08)
      The management of advanced prostate cancer has changed substantially with the availability of multiple effective novel treatments, which has led to improved disease survival. In the era of personalized cancer treatments, ...
    • Imaging in retroperitoneal soft tissue sarcoma. 

      Messiou, C; Morosi, C (2018-01)
      Patients with retroperitoneal sarcoma can present to a variety of clinicians with non-specific symptoms and retroperitoneal sarcomas can be incidental findings. Failure to recognize retroperitoneal sarcomas on imaging can ...
    • Imaging of testicular germ cell tumours. 

      Dalal, PU; Sohaib, SA; Huddart, R (2006-01)
      In testicular germ cell tumour (GCT), imaging plays a central role in assessment of tumour bulk, sites of metastases, monitoring response to therapy, surgical planning and accurate assessment of disease at relapse. The ...
    • Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945 

      Pillai, RG; Forster, M; Perumal, M; Mitchell, F; Leyton, J; Aibgirhio, FI; Golovko, O; Jackman, AL; Aboagye, EO (AMER ASSOC CANCER RESEARCH, 2008-05-15)
      The assessment of tissue-specific pharmacodynamics is desirable in the development of tumor-targeted therapies. Plasma deoxyuridine (dUrd) levels, a measure of systemic thymidylate synthase (TS) inhibition, has limited ...
    • The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNF alpha 

      Smith, MP; Sanchez-Laorden, B; O Brien, K; Brunton, H; Ferguson, J; Young, H; Dhomen, N; Flaherty, KT; Frederick, DT; Cooper, ZA; Wargo, JA; Marais, R; Wellbrock, C (AMER ASSOC CANCER RESEARCH, 2014-10)
      Recently, the rationale for combining targeted therapy with immunotherapy has come to light, but our understanding of the immune response during MAPK pathway inhibitor treatment is limited. We discovered that the immune ...
    • Immuno-oncology combinations: raising the tail of the survival curve. 

      Harris, SJ; Brown, J; Lopez, J; Yap, TA (2016-06)
      There have been exponential gains in immuno-oncology in recent times through the development of immune checkpoint inhibitors. Already approved by the U.S. Food and Drug Administration for advanced melanoma and non-small ...
    • Immuno-PET in Pontine Glioma: More Than Meets the Eye? 

      Oyen, WJG; Jones, C (2018-04)
    • Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma. 

      Tucker, ER; Tall, JR; Danielson, LS; Gowan, S; Jamin, Y; Robinson, SP; Banerji, U; Chesler, L (2017-08)
      Targeted inhibition of anaplastic lymphoma kinase (ALK) is a successful approach for the treatment of many ALK-aberrant malignancies; however, the presence of resistant mutations necessitates both the development of more ...
    • Immunodeficiency-related lymphoproliferative disorders: Prospective data from the United Kingdom Children’s Cancer Study Group Registry 

      Pinkerton, CR; Hann, I; Weston, CL; Mapp, T; Wotherspoon, A; Hobson, R; Kelly, DA; Vergani, D; Hadzic, D; Rees, L; Burke, M; Thomas, JA (2002-08)
      Clinical data and biological samples were prospectively collected in 42 children with lymphoproliferative disease (LPD) secondary to organ/bone marrow transplant-related immunosuppression (30: 11 liver, 10 heart/lung, 8 ...
    • Immunogenicity of self tumor associated proteins is enhanced through protein truncation. 

      Kottke, T; Shim, KG; Alonso-Camino, V; Zaidi, S; Maria Diaz, R; Pulido, J; Thompson, J; Rajani, KR; Evgin, L; Ilett, E; Pandha, H; Harrington, K; Selby, P; Melcher, A; Vile, R (2016)
      We showed previously that therapy with Vesicular Stomatitis Virus (VSV) expressing tumor-associated proteins eradicates established tumors. We show here that when cellular cDNA were cloned into VSV which retained their own ...
    • Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. 

      Nava Rodrigues, D; Rescigno, P; Liu, D; Yuan, W; Carreira, S; Lambros, MB; Seed, G; Mateo, J; Riisnaes, R; Mullane, S; Margolis, C; Miao, D; Miranda, S; Dolling, D; Clarke, M; Bertan, C; Crespo, M; Boysen, G; Ferreira, A; Sharp, A; Figueiredo, I; Keliher, D; Aldubayan, S; Burke, KP; Sumanasuriya, S; Fontes, MS; Bianchini, D; Zafeiriou, Z; Teixeira Mendes, LS; Mouw, K; Schweizer, MT; Pritchard, CC; Salipante, S; Taplin, M-E; Beltran, H; Rubin, MA; Cieslik, M; Robinson, D; Heath, E; Schultz, N; Armenia, J; Abida, W; Scher, H; Lord, C; D'Andrea, A; Sawyers, CL; Chinnaiyan, AM; Alimonti, A; Nelson, PS; Drake, CG; Van Allen, EM; de Bono, JS (2018-10-01)
      BACKGROUND: Understanding the integrated immunogenomic landscape of advanced prostate cancer (APC) could impact stratified treatment selection. METHODS: Defective mismatch repair (dMMR) status was determined by either loss ...
    • Immunohistochemical distinction of haematogones from B lymphoblastic leukaemia/lymphoma or B-cell acute lymphoblastic leukaemia (B-ALL) on bone marrow trephine biopsies: a study on 62 patients 

      Matutes, E (2011-08)
      Haematogones are normal, maturing B-cell precursors. They can be confused with neoplastic immature lymphoid cells of B lymphoblastic leukaemia/lymphoma or B-cell acute lymphoblastic leukaemia (B-ALL). Though multicolour ...
    • Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial. 

      Detre, SI; Ashley, S; Mohammed, K; Smith, IE; Powles, TJ; Dowsett, M (2017-03)
      The randomized, double-blinded Royal Marsden Tamoxifen Breast Cancer Prevention Trial in healthy high-risk women started in 1986 and is still blinded. Eligible participants (n = 2,471) were randomly assigned to tamoxifen ...